Table 3.
Baseline characteristics by responder status in the full analysis set
| Respondera (n=47) | Nonresponder (n=12) | |
|---|---|---|
| GL subtype, n (%) | ||
| Acquired | 18 (38.3) | 1 (8.3) |
| Congenital | 29 (61.7) | 11 (91.7) |
| Fasting leptin (ng/mL), mean (SD) | 1.5 (1.06) | 1.0 (0.52) |
| HbA1c (%), mean (SD) | 9.2 (2.02) | 6.2 (1.98) |
| HbA1c category, n (%) | ||
| <6.5% | 5 (10.6) | 9 (75.0) |
| ≥6.5% | 42 (89.4) | 3 (25.0) |
| ≥ 8.0% | 37 (78.7) | 2 (16.7) |
| Fasting TGs (mmol/L), mean (SD) | 17.9 (28.57) | 4.8 (8.62) |
| Fasting TG category, n (%) | ||
| <2.26 mmol/L | 7 (14.9) | 6 (50.0) |
| ≥2.26 mmol/L | 39 (83.0) | 6 (50.0) |
| ≥5.65 mmol/L | 23 (48.9) | 1 (8.3) |
| FPG (mmol/L), mean (SD) | 11.0 (4.84) | 6.1 (2.54) |
| ALT (U/L), mean (SD) | 104.7 (75.26) | 147.8 (211.11) |
| ALT above ULN, n (%) | 37 (78.7) | 7 (58.3) |
| AST (U/L), mean (SD) | 74.9 (58.66) | 83.9 (114.73) |
| AST above ULN, n (%) | 30 (63.8) | 3 (25.0) |
| Insulin use, n (%) | 31 (66.0) | 3 (25.0) |
| Antidiabetic medications, n (%) | 40 (85.1) | 7 (58.3) |
| Lipid-lowering medications, n (%) | 24 (51.1) | 5 (41.7) |
a
Responders are those patients with a ≥1% actual decrease in HbA1c or ≥30% decrease in fasting TGs at month 12 (or last observation carried forward).
ALT alanine aminotransferase, AST aspartate aminotransferase, FPG fasting plasma glucose, GL generalized lipodystrophy, HbA1c glycated hemoglobin, TGs triglycerides, ULN upper limit of normal.